Difference between revisions of "Ghostwriting"
| Line 1: | Line 1: | ||
{{Template:Pharma_Portal_badge}} | {{Template:Pharma_Portal_badge}} | ||
| − | == | + | ==Actonel== |
| − | |||
| − | |||
In September 2009, the Guardian reported that a leading British bone specialist is facing disciplinary action over accusations that he was involved in "ghost writing". The [[General Medical Council]] will summon Professor [[Richard Eastell]] from Sheffield University to a committee meeting. He admitted to agreeing to have his name used as first author of a study on the osteoporosis drug [[Actonel]] even though he did not have access to all the data on which the study's conclusions were based. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref> | In September 2009, the Guardian reported that a leading British bone specialist is facing disciplinary action over accusations that he was involved in "ghost writing". The [[General Medical Council]] will summon Professor [[Richard Eastell]] from Sheffield University to a committee meeting. He admitted to agreeing to have his name used as first author of a study on the osteoporosis drug [[Actonel]] even though he did not have access to all the data on which the study's conclusions were based. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref> | ||
| − | + | ==Caspper== | |
In September 2009, the Guardian reported that [[GlaxoSmithKline]] hired a ghostwriting programme named [[Caspper]] in which doctors could take credit for medical journal articles written by the company's consultants. According to documents held by a US law firm, the project was aimed at increasing America sales of the antidepressant paroxetine otherwise known as [[Paxil]] in the US and [[Seroxat]] in the UK. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref> | In September 2009, the Guardian reported that [[GlaxoSmithKline]] hired a ghostwriting programme named [[Caspper]] in which doctors could take credit for medical journal articles written by the company's consultants. According to documents held by a US law firm, the project was aimed at increasing America sales of the antidepressant paroxetine otherwise known as [[Paxil]] in the US and [[Seroxat]] in the UK. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref> | ||
Revision as of 09:19, 21 September 2009
|
This article is part of the Pharma_Portal project of Spinwatch. |
Actonel
In September 2009, the Guardian reported that a leading British bone specialist is facing disciplinary action over accusations that he was involved in "ghost writing". The General Medical Council will summon Professor Richard Eastell from Sheffield University to a committee meeting. He admitted to agreeing to have his name used as first author of a study on the osteoporosis drug Actonel even though he did not have access to all the data on which the study's conclusions were based. [1]
Caspper
In September 2009, the Guardian reported that GlaxoSmithKline hired a ghostwriting programme named Caspper in which doctors could take credit for medical journal articles written by the company's consultants. According to documents held by a US law firm, the project was aimed at increasing America sales of the antidepressant paroxetine otherwise known as Paxil in the US and Seroxat in the UK. [2]
Notes
- ↑ Bosely, S. British doctor faces action over claims of 'ghost writing' for US drug company. The Guardian. Accessed on 20 September 2009.
- ↑ Bosely, S. British doctor faces action over claims of 'ghost writing' for US drug company. The Guardian. Accessed on 20 September 2009.